Key result
Levosimendan improves refractory biventricular failure in one pediatric case of viral myocarditis and DCM.
Why the study?
Does levosimendan improve refractory cardiac failure in a child with viral myocarditis and dilated cardiomyopathy?
Case Report (n=1)
Does levosimendan improve refractory cardiac failure in a child with viral myocarditis and dilated cardiomyopathy?
Levosimendan may be a promising treatment for refractory cardiac failure in children with viral myocarditis and dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May warrant consideration in refractory pediatric cases; leaves open need for prospective trials to confirm safety and efficacy.
Intravenous positive inotropic agents play an important role in treating acute decompensation of patients with heart failure due to left ventricular systolic dysfunction. Levosimendan is a new positive inotropic agent having ATP-dependent potassium-channel opening, and calcium-sensitizing effects, which increases cardiac contractility and performance along with vasodilatatory action without increasing myocardial oxygen demand. We report a case of a 12-year-old girl with viral myocarditis, dilated cardiomyopathy, biventricular failure with severe left ventricular dysfunction, refractory to standard management, and who was successfully improved with levosimendan.
No takes yet. Share an insight, caveat, or question.
Kushwah et al. (2015) conducted a case report in Viral myocarditis, dilated cardiomyopathy, biventricular failure with severe left ventricular dysfunction (n=1). Levosimendan was evaluated on Clinical improvement. Levosimendan successfully improved the clinical condition of a 12-year-old girl with refractory biventricular failure due to viral myocarditis and dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: